Elizabeth Zawidzka Faha

Scientist i - Bioanalytical Sciences @Tr1X

San Diego, CA, US
EMAILS
e••••@tr1x.bio
MOBILE NUMBERS
+91 *********19

Signup · Get unlimited contacts

WORK HISTORY

Nov 2023 — Present

Scientist i - Bioanalytical Sciences @Tr1X

View department →

San Diego, CA, US

Functional lead responsible for developing analytical methods for potency assessment of Tr1x\'s novel cell therapy products. Lynchpin in internal and external collaborations required for successfully transferring methods from R&D to CMC, and then from CMC to Tr1x\'s CDMO partner.Responsibilities include: • Development of robust, phase-appropriate methods for assessing product potency.• Leading tech transfer of analytical methods to our CDMO partner. • Authoring technical documentation (non-GXP SOPs, data packages, assay development reports).• Collaborating with internal and external AD / QC groups to amend SOPs into a GxP appropriate format, design plans for assay validation and qualification studies.• Conducting on-site training for CDMO analysts to develop their expertise on method execution.

EDUCATION

2007 — 2011

Cranbrook Kingswood Upper School

High School

2012 — 2012

Center of Mind/Brain Sciences (CIMeC), University of Trento, Italy

Neuroscience

2018 — 2023

The Johns Hopkins University School of Medicine

Doctor of Philosophy - PhD, Cellular and Molecular Medicine

2000 — 2010

Szkola Jezyka Polskiego im. Adama Mickiewicza (Adam Mickiewicz Polish School), Sterling Heights, MI

Polish Language and Literature, Polish Studies

2011 — 2015

Harvard University

Bachelor of Arts (B.A.), Neurobiology

ABOUT ELIZABETH ZAWIDZKA FAHA

Driven and inquisitive immunologist, passionate about developing therapeutics that address unmet patient need• Strong technical proficiency in immunology and molecular biology.• I have 3 years of prior experience working with cross-functional teams to progress small molecule immunomodulators from the preclinical to the clinical stage.• My dissertation work at Hopkins honed my knowledge in immuno-oncology, CD8+ T cell dysfunction, and pre-clinical models of adoptive cellular therapy.• In my current role, I am building analytical methods to help progress Tr1x\'s cell therapy portfolio. I have led the development and optimization of methods to assess potency of 2 novel allogeneic T cell products, including assays used for clinical product release. • Core competencies: development and optimization of cell-based immunoassays and biochemical assays, multi-parametric spectral and conventional flow cytometry, cross-team collaboration.

This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.